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 Ideal combination or multi-antigen vaccines
 Safe and effective 
 Stabile individual components
 Provide broader coverage in immune response and protection
 Physiological or sub species diversity
 Reduce number of injections.
 Improves timeliness of immunizations.
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 Case Study:  Staphylococcus aureus tetra antigen vaccine
 Combination of two proteins and two polysaccharide – protein 
conjugates
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 Important pathogenesis mechanisms 
 Divalent cation scavenging
 Attaches to cell surfaces and host components resulting in
 Cell destruction by lytic enzymes
 Biofilms recalcitrant to antibiotic treatment
4
 Blood clots
 Evasion of opsonization and phagocytosis 
 Toxemia
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Challenges with multi-antigen formulations
 Compatibility with antigens
 Physical characteristics such as  pH, density, viscosity, size and size distribution, 
surface charge 
 Different mechanism of degradation for each component 
 Biochemical characteristics (e.g. adsorption, binding or coupling of an antigen).
 Varying levels of stability
 Conformational changes of antigens
 Surfactants can change conformational epitopes leading to loss of epitopes and 
decreased in vitro potency
5
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 Lipid components can alter hydrophobicity
 Analytical challenges
 Difficult to quantitate individual components 
 Separation techniques are limited 
 Tight interaction between adjuvant and antigen 
 Stability of the vaccine – shelf life 
 Dosage form and delivery 
Optimizing a formulation requires understanding of 


















Utilize Biophysical, Physical, Chemical and HPLC techniques 







10. Metal ions Select optimum solution conditions potential interactions 
can involve other components of the vaccines, including 
buffers, stabilizers, surfactants, adjuvants and 
preservatives
6
Characterization of protein antigens
 Thermo stability
 Determine as a function of pH - buffer
 This data will help guide the selection of formulation pH and buffer 
system
 Biophysical Methods
 Fluorescence spectroscopy:  tertiary structure
• Intrinsic: Trp
• Extrinsic:  ANS dye
7
 Circular dichroism:  secondary structure
 Differential scanning calorimetry:  monitor overall protein unfolding
 OD350:  detection of aggregation
 Real time and accelerated stability using various stress conditions 
 Analysis based on HPLC analysis such as reverse phase or IEX or SEC

























































































































































pH 6.9pH 6.6pH 6.2pH 6.0pH 5.4Days
5°C Prediction
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Major mechanism of degradation of Protein 1 is clipping in solution
Protein cannot be stabilized under aqueous conditions








1 5.5 0 40
2 7.5 0 40
3 6.5 5 20
4 5.5 10 40
5 7.5 0 0
6 6.5 5 20
7 7.5 10 0
8 5.5 10 0
9 5.5 0 0
10 6.5 5 20





































































Protein 2 IEX Analysis (5°C)
5C prediction
Days pH 5.4 pH 6.0 pH 6.2 pH 6.6 pH 6.9
0 2.5 2.5 2.6 2.6 2.6
1 2.5 2.5 2.6 2.7 2.8
2 2.6 2.6 2.7 2.8 2.9
3 2.6 2.7 2.8 2.9 3.1
25C prediction
Days pH 5.4 pH 6.0 pH 6.2 pH 6.6 pH 6.9
0 2.5 2.5 2.6 2.6 2.6
1 2.7 3.1 3.3 3.9 4.5
2 3.0 3.8 4.2 5.6 6.9




% Deamidation 1-wk 37°C
Design points above predicted value
97.2498
14.9789
X1 = C: NaCl
X2 = A: pH
Actual Factor































  C: NaCl  
  A: pH  
37°C
Based on multiple studies; pH, salt and 
temperature are dominant factors for 
stability 
















































































































Conjugate 2 @ 5ºC Conjugate 2 @ 25ºC
Drug product formulation rationale is based on stability











6.0 (5.8 to 6.2) 
Key driver to 
stability 
pH > 6.5 > pH 6.5 Absence of 
water  
pH  6.0 
Absence of salt 
and water 










Stability Typically for conjugates change is 
decrease in size followed by 





Drug Product : Target 6.5 ± 0.3 to maximize stability of all  
four components  
 
Combined vaccine unstable in solution - Need to freeze dry
When product is unstable in solution - Freeze dry
 Lyophilization 





 Process times 
• Freeze temperature
• Annealing
 Technologies applied 
 Freeze microscopy to determine 
collapse temperature






• Secondary drying time
 Success factors include
 Cake appearance 





 Binding to adjuvants
 Long term product stability  






 Protein chemical based assays
 HPLC
 in vitro potency
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Rationale for lyophilization





























































































Liquid  t = 4 wks
Degradation occurs upon storage when formulated 
as a liquid
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How do we characterize antigen-adjuvant formulations  
 Formulation 
 Co-formulate with antigen
 Mix and shoot at the clinic
 Stability
 Degradation mechanisms may be 
affected by an adjuvant
 Compatibility
 Long term stability of adjuvants 
 Compatibility of antigen-adjuvant 
 Analytics
 HPLC methods
• SEC, IEX, Reversed-phase
• Confirm multiple components do not 
interfere with each other
 Size of Particulate Adjuvants
• Dynamic Light Scattering, Mastersizer
 Antigen-adjuvant interactions
• Isothermal Titration Calorimetry
15
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• Solution conditions such as pH, 
buffer and other excipients Low 
dose stability
 Stability of vaccine antigen and 
adjuvant after reconstitution
 Integrity of Antigen in combination
• % binding assays (if applicable)
• Zeta Potential:  can predict binding based 
on electrostatic interactions
 Antigen Conformation
• Biophysical methods such as 
Fluorescence, CD or DSC can show if 
adjuvant is changing the antigen 
conformation
 In vitro potency
An example of Biophysical methods used to evaluate effect of 





































 Antigen B + ISCOMATRIX
Circular Dichroism Differential Scanning Calorimetry
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 These analysis provide confidence that there are no conformational changes in the 
antigen.
 These analysis need to be conducted on individual antigens only
-6.0E+06
Wavelength (nm) 0 20 40 60 80 100
0
Temperature (°C)
Differential binding of antigens to aluminum salts
Al conc. 
mg/mL 
% Antigen Bound to Al as AlPO4 
Protein 1 Protein 2 Conjugate 1 Conjugate 2 
0.75 2.6 100 18.1 13.8 
0.5 3.5 100 15.6 11.1 
0.25 0 100 14.6 11.4 






% Antigen Bound to Al as Al(OH)3 
Protein 1 Protein 2 Conjugate 1 Conjugate 2 
0.75 100 100 100 100 
0.5 100 100 100 100 
0.25 100 100 95.6 95 
0.125 100 100 71.2 87.6 
 
Antigens bound to Al(OH)3 cannot be recovered easily 













The protein binds tightly to AlPO4.  Could this help prevent deamidation?
Storage time of the vaccine may be limited at room temperature after 
reconstitution of the vaccine.  
Recommendation : deliver vaccine within four hours 
Summary – The challenges
 Formulation challenges 
 Selection of antigen candidates to maximize the immunological outcome
 With multiple antigens the final vaccine formulations may be optimized 
based on a  compromise – a sweet spot
 Lyophilization may be the optimal dosage form but is expensive
 Product stability
 Limited time between reconstitution of the vaccine and delivery
 Interaction with adjuvants 
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 Optimizing doses for each antigen in a clinical study
 Analytical challenges
 Multiple assays to quantitate each antigen and or monitor purity
 Example- If one of the antigens aggregates – SEC HPLC cannot be 
applied with multiple components 
 Combination vaccines are critical to the success of vaccination 
programs, and each new combination must be carefully studied to 
ensure comparable safety and immunogenicity of the individual 
components.
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